Patents by Inventor Mitchell Reff
Mitchell Reff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8603473Abstract: The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.Type: GrantFiled: April 9, 2008Date of Patent: December 10, 2013Assignee: Biogen Idec MA Inc.Inventors: Scott Glaser, Mitchell Reff, Tzung-Horng Yang, Xiufeng Wu, Paul Chinn
-
Publication number: 20130183288Abstract: The present invention provides non-fucosylated therapeutic antibodies. More particularly, the invention provides non-fucosylated anti-CD20, anti-CD23 and anti-CD80 antibodies, which show enhanced antibody effector functions. Also provided are cells expressing the non-fucosylated antibodies and therapeutic methods using the non-fucosylated antibodies.Type: ApplicationFiled: March 28, 2008Publication date: July 18, 2013Applicant: BIOGEN IDEC INC.Inventors: Mitchell Reff, Kandasamy Hariharan, MacLaren Ann, Sisk William
-
Patent number: 7604989Abstract: The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.Type: GrantFiled: July 10, 2002Date of Patent: October 20, 2009Assignees: Johns Hopkins University, Biogen Idec Inc.Inventors: Mitchell Reff, Eric Ailor, Michael J. Betenbaugh, Bruno Figueroa, Jr., Marie Hardwick
-
Publication number: 20090041758Abstract: The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.Type: ApplicationFiled: April 9, 2008Publication date: February 12, 2009Applicant: Biogen Idec MA Inc.Inventors: Scott Glaser, Mitchell Reff, Tzung-Horng Yang, Xiufeng Wu, Paul Chinn
-
Publication number: 20080089893Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.Type: ApplicationFiled: July 25, 2001Publication date: April 17, 2008Applicant: IDEC Pharmaceuticals CorporationInventors: Darrell Anderson, Nabil hanna, Ronald Newman, Mitchell Reff, William Rastetter
-
Publication number: 20070065435Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.Type: ApplicationFiled: August 7, 2006Publication date: March 22, 2007Applicant: Biogen Idec MA Inc.Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
-
Publication number: 20070065434Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.Type: ApplicationFiled: August 7, 2006Publication date: March 22, 2007Applicant: Biogen Idec MA Inc.Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
-
Publication number: 20060121028Abstract: Monoclonal anti-human CD20 antigen binding antibodies containing human IgG3 constant domains are provided. These antibodies possess effector functions that render them well suited for use in therapeutic methods, especially treatments wherein inhibition of B cell function or B cell number is therapeutically desirable.Type: ApplicationFiled: January 20, 2006Publication date: June 8, 2006Applicant: Biogen Idec Inc.Inventor: Mitchell Reff
-
Publication number: 20060073147Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.Type: ApplicationFiled: September 21, 2005Publication date: April 6, 2006Applicant: Biogen Idec MA Inc.Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
-
Publication number: 20050186205Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chim eric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.Type: ApplicationFiled: October 4, 2004Publication date: August 25, 2005Inventors: Darrell Anderson, Nabil Hanna, John Leonard, Roland Newman, Mitchell Reff, William Rastetter
-
Publication number: 20050163782Abstract: The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.Type: ApplicationFiled: June 28, 2004Publication date: July 28, 2005Applicant: Biogen Idec MA Inc.Inventors: Scott Glaser, Mitchell Reff, Tzung-Horng Yang, Xiufeng Wu, Paul Chinn
-
Publication number: 20050118175Abstract: Methods for inhibiting IgE production in a human subject using anti-CD23 antibodies.Type: ApplicationFiled: December 6, 2004Publication date: June 2, 2005Applicant: Biogen Idec MA Inc.Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
-
Publication number: 20050106222Abstract: A new recombinant protein production methodology has been discovered for expression of genes of interest. This should be useful for low or poorly expressing genes and in cellular production of high levels of proteins when such high levels may be detrimental or stressful to cells. Isolated polynucleotides encoding a spliced form XBP-1, ATF6, and eIF2? S51A are disclosed. Expression vectors comprising these polynucleotides are useful in increasing the specific cellular productivity in a cell expressing a polypeptide of interest by augmenting the unfolded protein response in a cell. Finally, methods to increase specific cellular productivity in mammalian cells using the above mentioned polynucleotides are also disclosed.Type: ApplicationFiled: June 10, 2004Publication date: May 19, 2005Inventors: Eric Ailor, Mitchell Reff
-
Publication number: 20050054833Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.Type: ApplicationFiled: September 28, 2004Publication date: March 10, 2005Applicant: Biogen Idec Inc.Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
-
Publication number: 20030157641Abstract: Described herein is a novel expression system for producing multiple gene products of interest from a single polycistronic construct. In particular, the expression system contains a polycistronic vector capable of expressing functional antibodies in eukaryotic host cells, which vector contains at least the following elements operably linked in the 5′ to 3′ orientation: a promoter operable in a eukaryotic cell; a DNA sequence encoding at least the variable region of an antibody light chain; an internal ribosome entry site (IRES); and at least one DNA sequence encoding an antibody heavy chain. Also disclosed are mammalian cells containing the polycistronic expression vector, and a method of producing functional antibodies in mammalian cells transfected with the polycistronic expression vector.Type: ApplicationFiled: November 18, 2002Publication date: August 21, 2003Applicant: IDEC Pharmaceuticals CorporationInventors: Mitchell Reff, Richard Barnett